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Abstract
Objective: RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the
circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in
a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals’ proprietary Adjuvant Systems AS02A or AS01B.A
recent trial of the RTS,S/AS02A and RTS,S/AS01B vaccines evaluated safety, immunogenicity and impact on the development
of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of
RTS,S/AS02A and RTS,S/AS01B on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent
parasitemias.
Design: The distribution of csp sequences and the MOI of the infecting strains were examined at baseline and in break-
through infections from vaccinated individuals and from those receiving a non-malarial vaccine.
Setting: The study was conducted in Kombewa District, western Kenya.
Participants: Semi-immune adults from the three study arms provided isolates at baseline and during break-through
infections.
Outcome: Parasite isolates used for determining MOI and divergence of csp T cell–epitopes were 191 at baseline and 87
from break-through infections.
Results: Grouping recipients of RTS,S/AS01A and RTS,S/AS02B together, vaccine recipients identified as parasite-positive by
microscopy contained significantly fewer parasite genotypes than recipients of the rabies vaccine comparator (median in
pooled RTS,S groups: 3 versus 4 in controls, P=0.0313). When analyzed separately, parasitaemic individuals in the RTS,S/
AS01B group, but not the RTS,S/AS02A group, were found to have significantly fewer genotypes than the comparator group.
Two individual amino acids found in the vaccine construct (Q339 in Th2R and D371 in Th3R) were observed to differ in
incidence between vaccine and comparator groups but in different directions; parasites harboring Q339 were less common
among pooled RTS,S/AS vaccine recipients than among recipients of rabies vaccine, whereas parasites with D371 were more
common among the RTS,S/AS groups.
Conclusions: It is concluded that both RTS,S/AS vaccines reduce multiplicity of infection. Our results do not support the
hypothesis that RTS,S/AS vaccines elicit preferential effects against pfcsp alleles with sequence similarity to the 3D7 pfcsp
sequence employed in the vaccine construct.
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The morbidity and mortality attributable to malaria in Africa is
reported to be on the decline, thanks to the increased funding from
philanthropy and governments [1–3] that has enabled deployment
of tools such as insecticide-treated nets [4] and artemisinin-based
combination therapies [5]. To sustain this momentum and thereby
allow African countries to reap the economic benefits that would
result from reducing the annual toll of 300 to 500 million malaria
cases, a larger armamentarium of malaria control measures are
required. There is hope that a malaria vaccine will soon be added
to the malaria control toolkit [6].
The most successful malaria vaccine to date is RTS,S, a
recombinant hybrid molecule expressed in yeast, in which the
partial sequence of circumsporozoite protein (CSP), central
tandem repeat, and carboxyl-terminal regions are fused to the N
terminal of the S antigen of hepatitis B virus (HBs Ag) in a particle
that also includes the un-fused S antigen. These antigens are
administered with the AS02A, an oil-in-water based Adjuvant
System containing the immunostimulants monophosphoryl lipid A
(MPL) and Quillaja saponaria fraction 21 (QS21; Antigenics, New
York, NY, USA) or a liposome based adjuvant system (AS01B)
containing the same immunostimulants [7]. In experimentally
infected volunteers, RTS,S/AS impact on P. falciparum parasitemia
was evident as either sterile protection or delay in the onset of
parasitemia [8–13].
In parallel, GSK Biologicals has co-developed with the Walter
Reed Army Institute of Research (WRAIR) a more immunogenic
formulation of RTS,S based upon the AS01B Adjuvant System. In
pre-clinical comparisons to RTS,S/AS02A in mice and monkeys,
RTS,S/AS01B elicited equivalent CSP-specific antibody and
greater and more sustained cellular immune responses [14–16].
Encouraged by these results, we have undertaken comparative
trials of RTS,S/AS01A and of RTS,S/AS02B in malaria naı ¨ve
[13] and malaria experienced adults [17]. In a number of clinical
trials, three doses of RTS,S/AS02A, RTS,S/AS02D or RTS,S/
AS01E have provided children under 5 with a vaccine efficacy of
up to 59% against clinical malaria and up to 65.9% against P.
falciparum infection, [18–23].
The CSP is the predominant protein found on the surface of the
sporozoite. Studies of the genetic diversity of the gene encoding
the csp of P. falciparum have demonstrated the existence of high
levels of genetic polymorphisms in isolates from different areas in
Africa [24]. Because of this and the fact that the RTS,S vaccine
contains only the csp allele of laboratory clone 3D7, it is necessary
to determine whether the monovalent 3D7 RTS,S/AS vaccine
will elicit a preferential effect against homologous alleles. Such an
effect could lead to the development of vaccine insensitive parasite
populations and ultimately to the failure of RTS,S-based vaccines
[8].
The key polymorphic sites in the csp gene which are
encompassed by the RTS,S antigen are the T-cell epitopes at
the carboxy-terminus of the protein, designated Th2R and Th3R.
Polymorphisms in these epitopes were the focus of the evaluation
of strain-specificity of RTS,S among adult Gambian men [25]. No
strain-specific effect of RTS,S/AS02A on malaria parasites was
found, nor were the average number of genotypes (multiplicity)
carried during post-vaccination parasitaemia different among
vaccinated men and controls. The recent analysis of csp sequences
and clone multiplicity in 521 parasite isolates from Mozambique
children under 5 years who participated in a large Phase II study
of the efficacy of RTS,S/AS02A confirmed the previous finding of
no significant effect of csp sequences but found a small but
significant decrease in the multiplicity of infections in post-
vaccination parasitemias among those with asymptomatic infec-
tions who had received RTS,S/AS02A [18,26].
The present report is based upon specimens obtained in the
context of a comparative safety and immunogenicity trial of two
RTS,S formulations, RTS,S/AS02A and RTS,S/AS01B, conduct-
ed in 255 malaria-experienced adults in Kenya [17]. This original
trial examined efficacy as a secondary endpoint, but was not
powered to compare clinical efficacy between formulations. In that
study, anti-CS antibody geometric mean titers were significantly
greater with RTS,S/AS01B compared to RTS,S/AS02A, and
vaccine efficacy in the RTS,S/AS01B group was 29.5% (95% CI:
215.4 to 56.9) and 31.7% (95% CI: 211.6 to 58.2) in the RTS,S/
AS02A [17]. Here, we test for evidence of genotypic selection on
the pfcsp locus, and for any effect of the RTS,S vaccine
formulations on parasite multiplicity.
Methods
Ethics statement
Details of scientific and ethical protocol approval for these
studies have been reported [17]. The clinical trials gov identifier
for this study is NCT00197054 and the GSK Study ID number is
104743 (Malaria-044).
Study area, population and vaccine trial
The population is primarily Luo who engage in subsistence
farming and related industries. Malaria epidemiology in this
region is holoendemic. Intense transmission occurs primarily by
bites of the Anopheles gambiae mosquito. P. falciparum parasitemia is
present in over 90% of malaria cases. The ‘‘long rainy season’’ of
late March through May produces intense transmission from April
through August while the ‘‘short rainy season’’ of October through
December produces less intense transmission from November
through January. Cumulative malaria attack rates are about 95%
during the long rains and 75% during the short rains. All
individuals in this population are parasitemic multiple times over a
lifetime.
Samples for molecular analysis were obtained during the course
of a vaccine trial that was carried out in Kombewa district,
Nyanza Province, Western Kenya. Witnessed, informed consent
was obtained from all adult subjects before screening. Following
screening, 255 adult Kenyan volunteers between 18 and 35 years
were enrolled for a double-blind randomised controlled trial. 85
volunteers were randomized to each of three groups receiving
RTS,S/AS02A, RTS,S/AS01B or rabies vaccine (RabipurH; Chiron
Behring GmbH) in 3 doses. Enrolment took place in July and
August 2005, as the annual ‘‘long rains’’ were ending. Vaccination
occurred from August to October 2005, and administration of all
three doses to all participants was completed before the ‘‘small
rains’’ commenced. One week prior to vaccine Dose 3, all
volunteers were presumptively treated with one dose of MalaroneH
(atovaquone and proguanil hydrochloride, GSK, Uxbridge, UK)
administered daily for three days under direct observation by the
study staff. Blood samples for genotyping were collected at
enrollment and during weekly blood draws for active detection
of infection (ADI) that started two weeks after dose 3 of Malarone
and continued for 14 weeks (Figure 1). Samples were also collected
during passive case detection in all volunteers presenting with
symptoms consistent with malaria during the same observation
period.
Blood sample collection and DNA extraction
Whole blood collected in K2 EDTA tubes were labeled with
unique sample identifier number. DNA was extracted from the K2
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Valencia, CA, USA). DNA samples were stored at 280uC until use.
CSP genotyping
Primers that bind to conserved sequences flanking the Th2R and
Th3R region of P. falciparum csp gene were used in a nested PCR to
amplify a 361 base pair fragment covering nucleotides 826 to 1186 of
the csp gene (numbering from the first ATG of the 3D7 pfcsp mRNA
sequence PFC0210c accessed at www.plasmodb.org) using previously
described primers and conditions [26], as follows. The PCR reagents
were obtained from Applied Biosystems (Banchburg, NJ, USA). In
the first-round of PCR, amplification was carried out in a 20 mL
reaction volume containing 16 PCR buffer, 1.5 mM MgCl2,
250 mMo fe a c hd N T P s ,2mL of genomic DNA extracted from
200 mL of whole blood, and 1 U of AmpliTaq Gold. Primers were
used at a concentration of 300 nM each. Amplification was
performed in a DNA Thermal Cycler (Tetrad PTC-225, MJ
Research Inc., Watertown, Massachusetts, USA). The amplification
conditions were: an initial denaturation of 95uCf o r3 m i n u t e s
followed by 40 cycles of 1 minute at 95uC, 1 minute at 60uCa n d
1m i n u t ea t7 2 uC followed by a final extension step at 72uCf o r
10 minutes. The second-round of PCR contained 1 mLo ft h e
primary amplicons in 200 nM of each primer in 16buffer as above.
Amplification conditions were as for the primary PCR. 5 mlo ft h e2
nd
round PCR products were monitored on a 2.0% agarose gel in
1xTAEbuffer to check thequality, size and yieldof the PCRproducts
before proceeding to product purification and sequencing, using
between 10 and 120 ng of PCR product as previously described (26).
The sequence of every PCR product was proof-read on two strands
by the same investigator. A second investigator read a random QC
sample of ,40% of all sequences on both strands, and also checked
all sequences deemed to be mixed or ambiguous independently from
raw sequencer output. For each double-read sequence a consensus
was reached or the assay repeated. Data was collated from all isolates
with a single csp allele, or where a clear majority allele could be
unambiguously identified. In mixed genotype infection, a majority
clone was recognised if, at each mixed allele polymorphic nucleotide
position, one residue dominated over others present, and this
dominance was clearly discernable on both DNA strands.
Genotyping of msp-1 and msp-2 for determination of
MOI
Allelic family-specific, nested PCR of 2 polymorphic regions of
P. falciparum genes, namely msp-1 block 2 and msp-2 block 3 were
used to detect the genetic structure of the parasite populations
essentially as previously described [27] with minor modifications of
primer annealing temperatures to optimize performance in our
PCR machine (annealing temperatures for nest 1 amplification
were 56uC for msp -1, and 58uC for msp-2; nest 2 annealing
temperatures were 60uC for msp-1 and 65uC for msp-2 ). Following
electrophoresis, staining with ethidium bromide and observation
under ultra-violet illumination, bands corresponding to different
parasite allelic forms were distinguished and counted and the
number of genotypes for msp-1 and msp-2 loci determined. Gels
were double-scored independently by 2 investigators, and either
consensus reached or the assay repeated. Each band seen in a gel
lane was considered to represent a P. falciparum population that
shares a single allelic variant, i.e. this population represents a
distinct genotype. The minimum number of genotypes at each
locus was determined for each sample and the results entered in an
excel worksheet.
Data processing and statistical analyses
Analyses were performed according to a plan developed prior to
data collection. Data were analyzed for three cohorts in an
according to protocol (ATP) analysis: RTS,S/AS02A recipients,
RTS,S/AS01B recipients, and rabies control vaccine recipients.
We also analysed pooled data from both RTS,S/AS02A and
RTS,S/AS01B recipients. The endpoint for assessing strain
specificity of the vaccine was the relative proportion of non-
vaccine type (3D7/NF54) alleles for each of the polymorphic
amino acids sites at Th2R and Th3R in the combined RTS,S
group versus controls. The primary analysis included single and
clear majority alleles and the combined RTS,S group was
compared to controls by Fisher exact test. Secondary analysis
included comparisons of each of the vaccine formulations (RTS,S/
AS01A and RTS,S/AS02B) versus control as well as an analysis
taking into account mixed alleles by including all available
sequence data (data not shown; analysis did not alter results as
there were few such infections in our dataset).
The distribution of the number of amino acids in the Th2R and
Th3R region different from vaccine type was also calculated and
groups were compared by Wilcoxon Rank Sum tests. Descriptive
statistics of the number of genotypes in each allelic family of msp-1
and msp-2 (MOI) were computed and groups were compared by
Wilcoxon Rank Sum tests and Gamma regression analysis
adjusted for parasite density and age (as previously described)
[26]. Primary analysis compared pooled RTS,S groups versus
Figure 1. Study events for RTS,S clinical trial in semi-immune adults in Kombewa, Nyanza Province, Western Kenya. ADI=active
detection of infection. The ADI period was 14 weeks and began 2 weeks after the third immunization.
doi:10.1371/journal.pone.0007849.g001
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formulation versus controls. All tests are 2-sided at 5% significance
level and no adjustments for multiplicity were applied. Analyses
were performed in SAS, version 9.1.
Results
Study events and timing
Study events are summarized in Figure 1.
Samples analyzed
The study enrolled 255 subjects that were randomized into
three study arms of 85: RTS,S/AS01A, RTS,S/AS02B and rabies
vaccine. At enrolment, 44 scheduled samples were not evaluable
either because of PCR failure, had clotted or were not collected.
Of the remaining 211 samples, 191 individuals (90.5%) were found
to harbor msp1 and/or msp2 alleles as detected by PCR and their
distribution in the vaccine cohorts is shown in Table 1. Single or
clear majority pfcsp allele sequence was obtained from the csp gene
of 146 of 211 (69.2%) of these pre-immunization specimens.
During ADI and at cross-sectional surveys, 93 individuals were
identified as having malaria parasites as detected by blood film.
Eighty-five of these (91.4%) were successfully evaluated for MOI
and 87 (93.6%) for csp sequences and their distribution in the
vaccine cohorts is shown in Table 1.
Multiplicity of infection
The number of distinguishable alleles for MSP1 and MSP2
genes was determined for each parasite isolate and the largest of
these numbers was considered the ‘‘multiplicity of infection’’
(MOI) of that sample. Figure 2 shows the distribution of MOI at
enrollment (panel A) and during ADI (panel B). At enrollment, the
mean (Standard Deviation) MOI was similar in all groups
(RTS,S/AS02A: 2.32 (1.31), RTS,S/AS01B: 2.37 (1.43), and
rabies vaccine 2.57 (1.40); median 2 for all groups). Incident
infections identified by blood film during post-vaccination follow-
up displayed a higher overall MOI than was observed at
enrollment (Figure 2, panel B). Also, during the ADI period, a
significant reduction in MOI was observed in the pooled RTS,S
(median 3) versus controls (median 4) (p=0.031). Modeling MOI
by Gamma regression models confirmed these results (unadjusted
p=0.038, adjusted p=0.019 for parasite density and age). The
reduction in MOI was more pronounced for the RTS,S/AS01B
group (p=0.034) than for the RTS,S/AS02A group that did not
reach statistical significance (p=0.130).
Th2R and Th3R sequences
At enrolment, isolates were genotyped at the 2 polymorphic
regions of the csp gene to determine the prevalence of 3D7-like
alleles compared to that of non-3D7-like alleles at each
polymorphic amino acid position in the Th2R and Th3R epitopes
in the vaccine and control groups.
Figure 3 shows the proportion of isolates that contained non-
vaccine residues in the csp Th2R and Th3R at enrollment.
Overall, the prevalence of non-3D7 alleles at particular amino
acids in the 2 polymorphic regions Th2R and Th3R was similar
between treatment arms, except for Q339 in Th2R which was at a
lower prevalence in the vaccine groups (pooled RTS,S versus
control P=0.0004).
Parasites from break-through infections occurring over a 14
week period starting 2 weeks post dose 3 (the ADI period) were
also genotyped at Th2R and Th3R csp gene to evaluate if the
protection conferred by RTS,S is strain specific, i.e. only against
parasites with a csp sequence similar to vaccine type (3D7). No pfcsp
allele identical to the 3D7 allele used in the vaccine construct was
found in any of the break-through infections (during ADI) in the
three arms of the study (Supplementary Figure S1). The average
number of differences to the vaccine allele was 8 (range=6–12)
and was similar between treatment groups (pooled RTS,S versus
control P=0.904).
Table 1. Summary of sample numbers used for multiplicity of
infection and csp sequence analysis.
Sample
numbers RTS,S/AS01B RTS,S/AS02A Rabies vaccine Total
Enrolment MOI 65 65 61 191
Enrolment csp 49 49 48 146
ADI MOI 22 26 37 85
ADI csp 22 28 37 87
doi:10.1371/journal.pone.0007849.t001
Figure 2. Multiplicity of infections at enrollment and during
active detection of infection. Minimum number of clones for
vaccine and control groups at enrollment and during the active
detection of infection (ADI) period. At enrollment, denominators were
n=65 for RTS,S/AS01B, 65 for RTS,S/AS02A and 61 for rabies. During the
ADI period, the denominators were n=22 for RTS,S/AS01B, n=26 for
RTS,S/AS02A and n=37 for rabies.
doi:10.1371/journal.pone.0007849.g002
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vaccine type residues in the csp Th2R and Th3R during the ADI
period. In the RTS,S/AS01B, we observed a significant difference
in the prevalence of non 3D7-type Q339 residue in Th2R, which
was higher in RTS,S/AS01B recipients as compared to controls
(P=0.04). The D371 non-vaccine type residue in Th3R, was less
prevalent in the RTS,S groups, this difference reaching statistical
significance for pooled RTS,S groups versus controls (P=0.02).
There were no other significant differences between the groups at
any position in either Th2R and Th3R (Supplementary Tables S1
and S2).
Analysis of pfcsp haplotypes at baseline
We further explored this diversity by examining the prevalent
haplotypes at both the Th2R and Th3R sequences among the
baseline sample set collected in July 2005, prior to vaccination. A
sequence of 8 digits for Th2R and 6 digits for Th3R defined the
haplotypes, with 1 indicating vaccine type residue and 0 non-
vaccine type residue at each polymorphic amino acid position
(Supplementary Table S3). The non-vaccine haplotypes at
baseline differed from the vaccine haplotypes at more than one
amino acid residual, as previously observed [25]. Among 146
isolates contributing a single or clear majority pfcsp sequence, we
observed 14 different Th2R haplotypes with 4 common
haplotypes accounting for 76.6% of the sequences determined.
There were 12 Th3R haplotypes identified, but most of these were
rare, with 3 common haplotypes accounting for 82.8% of the
sequences. One isolate collected at baseline encoded both Th2R
and Th3R epitopes identical to the vaccine sequence.
Table 2 depicts associations among these common haplotypes,
showing that the Th2R and Th3R epitope sequences do not
randomly assort, and that the possible combinations that can exist
in a single pfcsp molecule appear to be constrained. In particular
there is a statistically significant association between the most
common Th2R haplotype (10010111; see Table 2 for explanation
of the binary code) and the most common Th3R haplotpye
(111110), which indicates these two occur together more often
than would be expected if there was random assortment between
the two epitope sequences (O.R. 720, 95% C.I. 84.2–6155.1,
P,0.0001).
Interestingly, we also observed 16 sequences with the N313K
amino acid substitution upstream of the Th2R epitope, but this
mutation did not occur with either of the most common Th2R and
Th3R sequences. Rather, all were of a single allele: 10010011 at
Th2R and 111010 at Th3R. This identical allele was also common
among isolates identified by active detection of infection: of 87
single or majority pfcsp sequences determined during post-
vaccination, 12 carried the N313K, all of which were 10010011
at Th2R and 111010 at Th3R. However, the most common
Th2R haplotype among the baseline samples (10010111) was
absent among the 87 ADI isolates. Similarly the Th3R haplotype
111110, which was very common among baseline isolates
(Table 2), was found in only 5 of the 87 ADI isolates. These
differences suggest that substantial fluctuations in the circulating
parasite genotypes can occur between transmission seasons, as
previously observed for markers of drug resistance [28]. The
distributions among randomized treatment groups of the four most
common Th2R haplotypes, and the three most common Th3R
haplotypes were not found to differ significantly at baseline from
the expected ratio of 1:1:1 (P.0.1 in each case).
Discussion
In a large clinical trial involving children under 5 years, three
doses of RTS,S/AS02A have shown efficacy in extending time to
first episode of clinical malaria or P. falciparum infection, with
measurable benefit still evident 18 months and 48 months later
[18,19,21]. In further studies of RTS,S/AS02D and RTS,S/
AS01E in infants and children up to 17 months of age in
Figure 3. Distribution of csp non-vaccine type alleles at
enrollment. Percentage distribution of the polymorphic amino acids
sites in the Th2R and Th3R regions in the RTS,S vaccine and control
groups at enrollment.
doi:10.1371/journal.pone.0007849.g003
Figure 4. Distribution of csp non-vaccine type alleles during
period of active detection of infection. Percentage non-vaccine
type alleles for the polymorphic amino acids sites in the Th2R and Th3R
regions of the RTS,S vaccine and control groups during the ADI period.
doi:10.1371/journal.pone.0007849.g004
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malaria and up to 65.9% against P. falciparum infection was
observed [20,22,23]. While there are many approaches that can be
utilized to improve on this level of protection, for example by
combining different antigens that attack the parasite at different
life cycle stages, improved adjuvant activity may also provide an
increase in immune responsiveness [29]. Recent preclinical trials
showed augmented antibody and cell-mediated immune responses
when RTS,S was combined with a new Adjuvant System (RTS,S/
AS01B) compared to another formulation (RTS,S/AS02A) [14–
16]. Clinical trials that have just been concluded by our institutions
have confirmed these findings [13,17]. In this study, we have
analyzed the molecular impact of RTS,S/AS02A and RTS,S/
AS01B on MOIs and csp T-cell epitopes at baseline (191 isolates for
MOI and 146 for csp) and during break-through infections (85
isolates for MOI and 87 for csp) from a phase IIb trial in Kenyan
semi-immune adults conducted in 2005 by Polhemus and
colleagues [17].
We used size polymorphisms in the msp-1 and msp-2 genes to
determine the MOI [27]. At enrollment, mean MOI was 2, and
was not different between the vaccine or control cohorts (Figure 2)
suggesting that at baseline there was a comparable malaria-
immune status and that the individuals in these cohorts had
recently experienced similar malaria transmission conditions. As
shown in Figure 1, all volunteers were presumptively treated with
MalaroneH (atovaquone and proguanil hydrochloride, GSK, Ux-
bridge, UK) one week prior to administration of vaccine Dose 3
[23] and the presence of malaria parasites were monitored weekly
by microscopy from 14 days post dose 3 onwards. All confirmed
infections were then evaluated for MOI and for distribution of the
amino acid alleles in the Th2R and Th3R region of CSP. Despite
the presumptive clearance of malaria parasites, the overall MOI
for this period was higher than at enrollment (Figures 2). This may
represent differences in parasite detection thresholds, as parasite
positive individuals at enrollment were identified by PCR
amplification, and thus harboured lower density parasitaemia on
average versus positives identified by blood film examination
during ADI. Alternatively, seasonal differences in malaria
transmission may have contributed to the observed difference in
MOI in the two datasets. Break-through infections in RTS,S/AS
vaccinees contained fewer genotypes than controls (median 3
versus 4 P=0.0313), a finding that was slightly more pronounced
and reaching statistical significance for the RTS,S/AS01B
formulation (P=0.0340). However, the difference in the mean
MOI between the RTS,S/AS02A and the control was not
statistically significant. Overall, our pooled data from both malaria
vaccine groups are consistent with other studies that reported
reduction in MOI after vaccination with RTS,S/AS02A in
Mozambican children [26] but not with the results arising from
the trial in Gambian men where a reduction in MOI was not
observed.
During ADI, the proportion of isolates with non-vaccine type
residues was significantly different in vaccine vs control groups for
two individual amino acids: Q339 in Th2R and D371 in Th3R.
Non-vaccine type Q339 residue was increased while non-vaccine
type D371 was reduced in the vaccine arms. However, since these
differences were in opposite directions (Figure 4), and due to
multiplicity, it cannot be ruled out that these alterations occurred
by chance and therefore do not represent an overall effect.
Moreover, analysis of the baseline sequences revealed that, due to
chance, differences in prevalence of non-vaccine type residues
between treatment groups do occur prior to vaccination as well
(Q339). When including mixed alleles, Enosse et al. found more
isolates with non-vaccine residues at E333-Glu (Th2R) and K337-
Lys (Th2R) among the vaccine group compared to controls but
conversely found more non-vaccine residues at D374-Asp (Th3R)
in the control group [26]. Taking these observations together with
our findings at amino acid positions Q339 and D371, we do not
find strong support for the hypothesis that either RTS,S
formulation significantly alters pfcsp gene frequencies, either by
selection for escape mutants or deletion of specific vaccine-like
genotype subsets. In our Kisumu population, CSP sequences with
significant identity to the 3D7 vaccine allele were rare (Supple-
mentary Table S3); the detection of vaccine-mediated shifts in
allele frequencies may be more likely in other settings where
vaccine-like alleles are more abundant.
It was noted that the most abundant haplotypes in the baseline
sample were not common among post-vaccination isolates.
Further, certain specific substitutions were more common prior
to vaccination, and this was particularly noteworthy for the Q339
non-vaccine allele, which was common in both groups of
volunteers that were to receive the malaria vaccine, but by chance
was significantly less common among ADI parasite isolates from
recipients of the malaria vaccine (fig. 3). However, circulating
parasites in all participants were cleared with atovaquone-
proguanil treatment prior to the third vaccine dose, and therefore
the enrolment parasite population itself was not placed under
selection by vaccine-elicited immunity. This discontinuity between
pre-vaccination and ADI parasite samples is further exacerbated
by the fact that the two samples represent parasites from two
distinct, consecutive malaria seasons.
Our descriptive analysis of pfcsp haplotypes circulating prior to
vaccination provides evidence that the Th2R and Th3R display
non-random associations in the parasite population studied. Lack
of evidence of random assortment between two loci may indicate
functional constraints on the CSP protein that limit the possible
Table 2. Associations among the most common Th2R and Th3R haplotypes at enrolment, prior to clearance of parasitaemia.
3 most common Th3R sequences haplotypes
4 most common Th2R haplotypes 111110 (N=54) 111011 (N=37) 111010 (N=29)
10010111 (N=49) 48 0 0
10010011 (N=25) 0 2 20*
00010011 (N=22) 0 21 0
10010001 (N=15) 0 0 9
Haplotypes are depicted in binary code across either 8 (Th2R) or 6 (Th3R) variable amino acid positions, where 1 indicates the presence of the 3D7 (vaccine – like)
residue, and 0 depicts its substitution with another amino acid. The remaining 45 isolates were comprised of less common Th2R and Th3R sequences.
*16 of the sequences in this category also had the N313K mutation, upstream of the Th2R region.
doi:10.1371/journal.pone.0007849.t002
Molecular Impact of RTS,S
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7849amino acid combinations that are viable. It may also simply reflect
the close physical association of Th2R and Th3R sequences, such
that recombination events between the two sites are extremely
rare. Lack of recombination means that novel combinations that
arise in either epitope may be successfully propagated, carrying the
other epitope along with it unchanged, and so linkage patterns can
simply reflect recent evolutionary history. One interesting finding
was of a stable pfcsp allele - N313K, 10010011 at Th2R and
111010 at Th3R – that was relatively common both in 2005
(baseline sample) and 2006 (ADI sample). This suggests that future
studies of anti-CSP vaccines should consider haplotype-based
analysis for the evaluation of vaccine-elicited selection [29,30].
Such analysis requires large sequence sample sets, and was not
performed in the current study. It was noted that the most
abundant haplotypes in the baseline sample were not common
among post-vaccination isolates. We think this difference is best
explained by the fact that the baseline sample and the ADI sample
represent parasites circulating in two consecutive malaria seasons
and thus represents inter-season fluctuations in allele prevalences,
as has been observed for drug-resistance-associated loci [28]. All
subjects were enrolled prior to the start of the malaria season and
therefore infections in the baseline samples most likely represent
residual asymptomatic infections resulting from exposure in the
previous transmission season.
In conclusion, our results support previous indications that
RTS,S/AS vaccines can reduce MOI. This reduction was
statistically significant for RTS,S/AS01B. However, we are
cognizant that attempts to correlate MOI and risk of malaria
have been inconsistent [31–34] and therefore suggest caution
when interpreting any associations between vaccination-elicited
protection and effects of adjuvanted RTS,S on subsequent MOI.
The sequence data on the Th2R and Th3R region of csp presented
here do not support the hypothesis that RTS,S elicits strain-
specific vaccine selection effects. In future, haplotype-level analyses
of larger sample sets as RTS,S vaccines enter Phase III testing may
help to establish whether any observed individual amino acid
changes in breakthrough parasites represent the beginning of
vaccine-dependent cumulative selection for escape mutants of
malaria parasites.
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